Literature DB >> 17888986

Initial experience with hybrid palliation for neonates with single-ventricle physiology.

Christopher A Caldarone1, Lee Benson, Helen Holtby, Jia Li, Andrew N Redington, Glen S Van Arsdell.   

Abstract

BACKGROUND: Hybrid palliation consisting of bilateral pulmonary artery banding and ductal stenting (PAB/DS) is an emerging method to palliate neonates with functional single ventricles.
METHODS: Outcomes were reviewed for a newly established hybrid program. PAB/DS was performed in 18 patients for three indications: Norwood alternative (n = 11), pretransplant palliation (n = 5), and salvage (n = 2). Comparison is made with a concurrent group of 25 patients treated with a Norwood procedure.
RESULTS: Among Norwood-alternative patients, there were two deaths, followed by nine stage II procedures, with one death. One salvage patient died. All pretransplant palliation patients underwent subsequent transplantation, with one death 49 days after the transplantation. Three deaths were due to clearly defined technical errors, and one death (salvage patient) was due to an error in patient selection. Kaplan-Meier survival at 1 year was 68% for the hybrid patients. By indication, survival at 1 year was 80.0% for Norwood-alternative, 69.7% for pretransplant palliation, and 50.0% for salvage (p = 0.31). Overall Norwood survival at 1 year was 71.4% (p = 0.56 vs overall hybrid). Among Norwood-alternative survivors, combined (stage I and stage II) intubation times and lengths of stay in the intensive care unit and in the hospital tended to be shorter than Norwood survivors but did not reach statistical significance (9.6 +/- 6.9, 15 +/- 8, and 35.7 +/- 15.3 days versus 15.4 +/- 4.9, 23.5 +/- 16.7, and 50.5 +/- 43.6 days, respectively, p = NS).
CONCLUSIONS: Despite comparison with a well-established Norwood program, a newly established hybrid program provides initial results that are comparable with those obtained with the Norwood procedure, suggesting that the learning curve in the current era is relatively short. As refinements in patient selection and technical issues evolve, survival can be expected to rapidly improve.

Entities:  

Mesh:

Year:  2007        PMID: 17888986     DOI: 10.1016/j.athoracsur.2007.04.127

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

1.  Comparison of gastrointestinal morbidity after Norwood and hybrid palliation for complex heart defects.

Authors:  Scott L Weiss; Jeffrey G Gossett; Sunjay Kaushal; Deli Wang; Carl L Backer; Eric L Wald
Journal:  Pediatr Cardiol       Date:  2010-12-25       Impact factor: 1.655

2.  Hybrid palliation for neonates with hypoplastic left heart syndrome: current strategies and outcomes.

Authors:  Osami Honjo; Christopher A Caldarone
Journal:  Korean Circ J       Date:  2010-03-24       Impact factor: 3.243

3.  Stage 1 hybrid palliation for hypoplastic left heart syndrome--assessment of contemporary patterns of use: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database.

Authors:  Tara Karamlou; David Overman; Kevin D Hill; Amelia Wallace; Sara K Pasquali; Jeffrey P Jacobs; Marshall L Jacobs; Christopher A Caldarone
Journal:  J Thorac Cardiovasc Surg       Date:  2014-08-14       Impact factor: 5.209

4.  Hybrid stage I palliation for hypoplastic left heart syndrome has no advantage on ventricular energetics: a theoretical analysis.

Authors:  Shuji Shimizu; Toru Kawada; Dai Une; Toshiaki Shishido; Atsunori Kamiya; Shunji Sano; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2014-11-29       Impact factor: 2.037

5.  Hybrid stage I palliation for hypo-plastic left heart condition without a hybrid suite: suggestions for developing nations.

Authors:  S Anuradha; Raghavan Subramanyan; Ravi Agarwal; A Thomas Pezzella; K M Cherian
Journal:  Indian Heart J       Date:  2012-06-19

6.  Outcomes in Patients with Persistent Ventricular Dysfunction After Stage I Palliation for Hypoplastic Left Heart Syndrome.

Authors:  Emilie Jean-St-Michel; Devin Chetan; Steven M Schwartz; Glen S Van Arsdell; Alejandro A Floh; Osami Honjo; Jennifer Conway
Journal:  Pediatr Cardiol       Date:  2015-09-22       Impact factor: 1.655

Review 7.  Hypoplastic left heart syndrome: current considerations and expectations.

Authors:  Jeffrey A Feinstein; D Woodrow Benson; Anne M Dubin; Meryl S Cohen; Dawn M Maxey; William T Mahle; Elfriede Pahl; Juan Villafañe; Ami B Bhatt; Lynn F Peng; Beth Ann Johnson; Alison L Marsden; Curt J Daniels; Nancy A Rudd; Christopher A Caldarone; Kathleen A Mussatto; David L Morales; D Dunbar Ivy; J William Gaynor; James S Tweddell; Barbara J Deal; Anke K Furck; Geoffrey L Rosenthal; Richard G Ohye; Nancy S Ghanayem; John P Cheatham; Wayne Tworetzky; Gerard R Martin
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

8.  First-stage palliation strategy for univentricular heart disease may impact risk for acute kidney injury.

Authors:  Bryan H Goldstein; Stuart L Goldstein; Prasad Devarajan; Farhan Zafar; David M Kwiatkowski; Bradley S Marino; David L S Morales; Catherine D Krawczeski; David S Cooper
Journal:  Cardiol Young       Date:  2017-09-11       Impact factor: 1.093

Review 9.  Current status of the hybrid approach for the treatment of hypoplastic left heart syndrome.

Authors:  Yorikazu Harada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-12-05

10.  Outcomes of hybrid and Norwood Stage I procedures for the treatment of hypoplastic left heart syndrome and its variants.

Authors:  Ersin Erek; Selim Aydın; Bahar Temur; Mehmet Akif Önalan; Dilek Suzan; Müzeyyen İyigün; İbrahim Halil Demir; Ender Ödemiş
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-04-22       Impact factor: 0.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.